- Tenofovir DF (tenofovir disoproxil fumerate) is a nucleotide analogue that is commonly called tenofovir. The tradename in Europe is Viread.
- In low- and middle-income countries (LMIC) this is a white tablet with the same design.
- Standard adult dose: 1 x 300 mg tablet of tenofovir DF, once-daily. (Sometimes the same dose is referred to as 245 mg tenofovir disoproxil or 136 mg tenofovir).
- Tenofovir is recommended to be taken with food in Europe and with or without food in the US. Food increases tenofovir levels by about 30%. The benefit of taking tenofovir with food is likely to be more important when first starting treatment, if viral load is very high, or if you have resistance to other nukes.
- Side effects: kidney function, flatulence (wind), reduced bone mineral density (over first six months).
- Tenofovir is included with FTC in the fixed dose combination Truvada.
- Tenofovir is included, with FTC and efavirenz, in the fixed dose combintion Atripla.
- Other notes: tenofovir is cleared by the kidneys – monitoring for kidney toxicity, and not using tenofovir with other drugs that are cleared the same way, are important safety cautions.
Information on tenofovir side effects from the i-Base side effects guide.
The European patient leaflet and detailed Product Information for tenofovir are available in PDF format from this link at the European Medicines Agency (EMA) website.
The Patient Information is a simplified summary: what the drug is, why it is used, results from studies and cautions including side effects.
The Product Information is a detailed technical summary that you can access as a PDF file by clicking the ‘Product Information’ tab. It describes more precisely how the drug works and how it is processed by your body. This includes, for example, reported food interaction studies in terms of calories or fat content. It includes more details of the study results and a full list of side effects and drug interactions.